Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Biogen Idec Italia S.r.l
Femme et Homme Max 99 ans
Biogen Idec Italia S.r.l
MAJ Il y a 4 ans
Study for the satisfaction assessement of the treatment with Plegridy in patient with Multiple Sclerosis Studio per la valutazione della soddisfazione dei pazienti con Sclerosi Multipla all'utilizzo del farmaco Plegridy
The primary objective of the study is to investigate whether Peg-IFN beta-1a improves patients’ satisfaction in RRMS subjects unsatisfied with other injectable subcutaneous Interferons, as measured by...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Italia S.r.l
MAJ Il y a 4 ans
Experimental clinical trial regarding relapsing-remitTing Multiple Sclerosis newly diagnosed patients, not yet treated for the evaluation of the onset, the efficacy and speed of action of the treatment with BG00012 Studio clinico di tipo sperimentale in pazienti affetti da sclerosi multipla recidivante-remittente di nuova diagnosi, non ancora trattati per valutare l'esordio, l'efficacia e la velocità di azione del trattamento con BG00012
The primary objective of the study is to assess the early efficacy of treatment with BG00012 240 mg BID in the brain of newly diagnosed and naive-to-treatment patients with RRMS. L’obiettivo pri...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Biogen Idec Italia S.r.l
MAJ Il y a 4 ans
Study to evaluate the efficacy of cetirizine in the treatment of Flu-like syndrome (FLS) in patients with multiple sclerosis treated with interferoneβ
To evaluate the effectiveness of the administration of cetirizine 10 mg on the improvement of the symptoms of FLS. The primary objective of the study was the mean change in subjective seriousness of t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations